CPT1A could also support Castration-Resistant Prostate Cancer (CRPC) by supplying acetyl groups for histone acetylation and CPT1A variant 2 is also found to promote tumor invasion and metastasis (49, 50) Besides, knockdown of CPT1A could repress xenograft tumor initiation through inhibiting adipocytes’ tumor-promoting effects, which indicates CPT1A-dependent FAO as a target for anti-cancer therapeutics (51). This evidence concerns the gene CPT1A and neoplasm.